Evidence map›Paper›PMID 29769103›Full record

ReviewRadiation oncology (London, England)2018

The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.

C M van Leeuwen, A L Oei, J Crezee, A Bel, N A P Franken, L J A Stalpers, H P Kok

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 240 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06946238 narecruitingnot on this mapstarted 2025, after this paper: background citation

Accelerated Partial Breast Irradiation in One Fraction for Patients With Early-stage Disease and Favorable Histological Subtypes (Breast-1F).

TypeinterventionalSponsorIRCCS San RaffaeleRan2025 to 2035Enrolled311ConditionsBreast CancerArmsAdjuvant single-fraction accelerated partial breast irradiation
NCT07020780 narecruitingnot on this mapstarted 2025, after this paper: background citation

Five Fractions Ultrahypofractionated Whole Breast Radiotherapy and Simultaneous Integrated Boost to the Tumor Bed, for Breast Cancer Patients With Unfavorable Characteristics

TypeinterventionalSponsorIRCCS San RaffaeleRan2025 to 2035Enrolled458ConditionsBreast CancerArmsAdjuvant 5 fractions whole breast irradiation with simultaneous integrated boost to the tumor bed
3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Enhanced Antitumor Efficacy ofInternational journal of radiation oncology, biology, physics · 2026
    Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C M van LeeuwenDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands.
A L OeiDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands.
J CrezeeDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands.
A BelDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands.
N A P FrankenDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands.
L J A StalpersDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands.
H P KokDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, AZ, The Netherlands. h.p.kok@amc.uva.nl.

Funding

KWF Kankerbestrijding UvA 2012-5540
6 · The paper itself

Abstract

backgroundPrediction of radiobiological response is a major challenge in radiotherapy. Of several radiobiological models, the linear-quadratic (LQ) model has been best validated by experimental and clinical data. Clinically, the LQ model is mainly used to estimate equivalent radiotherapy schedules (e.g. calculate the equivalent dose in 2 Gy fractions, EQD METHODS AND MATERIALS: We performed a systematic literature search and found sixty-four clinical studies reporting α, β and α/β for tumours. Tumour site, histology, stage, number of patients, type of LQ model, radiation type, TCP model, clinical endpoint and radiobiological parameter estimates were extracted. Next, we stratified by tumour site and by tumour histology. Study heterogeneity was expressed by the I

resultsA large heterogeneity in LQ parameters was found within and between studies (I

conclusionsThe value of LQ parameters for tumours as published in clinical radiotherapy studies depends on many clinical and methodological factors. Therefore, for clinical use of the LQ model, LQ parameters for tumour should be selected carefully, based on tumour site, histology and the applied LQ model. To account for uncertainties in LQ parameter estimates, exploring a range of values is recommended.

Indexed as

Dose Fractionation, RadiationModels, StatisticalHumansLinear ModelsNeoplasmsFractionation sensitivityRadiosensitivityStudy heterogeneityα/β ratio

Identifiers

PMID29769103
PMCPMC5956964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.